Table 1.

Selected studies on prevalence of CRCI in younger and older adults.

Reference	Population	Treatment	Age (years)	Time during which testing was performed	Tests use/ measures	Cognitive domains tested	Results
Cruzado et al., 201410	81 colon cancer patients	Chemotherapy	Mean 67.0 (range 38–85)	Pre-chemotherapy. T2: post-chemotherapy. T3: 6 months from last chemotherapy	Neuropsychological testsa	Attention and visual-motor ability, executive function, verbal memory and verbal learning	Cognitive dysfunction in 37% at baseline, 37% at T2 and 39% at T3
Wefel et al., 201011	42 T1–3, N0–1, M0 breast cancer patients	Chemotherapy	Mean 48.8 (range 33–65)	At baseline: before chemotherapy. T2: during and shortly after chemotherapy [2.9 (SD, 0.59) or 7 (SD, 1.4) months after baseline). T3: 7.7 months (SD, 3.1) after completion of chemotherapy	Neuropsychological testsa	Attention, processing speed, learning and memory, executive function	–Cognitive dysfunction in 21% at baseline, 65% at T2 and 61% at T3. –At T3, 29% has evidence of new delayed cognitive decline. –Cognitive decline most common in learning and memory, executive function, and processing speed.
Kohli et al., 20079	595 newly diagnosed solid tumor patients	Chemotherapy or radiation therapy or both	Mean 56.3 (range 29–92)	At baseline: within 2 weeks before initiation of chemotherapy. T2: within 2 weeks of completing treatment. T3: 6 months after completing treatment	Symptom Inventory	Concentration, memory	–Concentration problems in 48% at baseline, 67% at T2 and 58% at T3. –Problems with memory in 53% at baseline, 67% in T2 and 68% in T3.
Hurria et al., 200659	45 stage I–III breast cancer patients; 84	Chemotherapy	Mean 70 (range 65–84)	Before chemotherapy. T2: 6 months after chemotherapy	Squire Memory Self-rating Questionnaire	Self-reported learning, working memory and remove learning	51% perceived decline in memory from baseline to T2.
Hurria et al., 20063	31 stage I–III breast cancer patients	Chemotherapy	Mean 71 (range 65–84, SD 5)	Before chemotherapy. T2: 6 months after chemotherapy	Neuropsychological testsb	Attention, verbal memory, visual memory; and verbal, spatial, psychomotor and executive functions	Cognitive dysfunction in 11% at baseline, 29% at T2.

Impairment defined as:

^aScoring 2.0 SDs below published norms on one test or 1.5 SDs below published norms on two tests;

^bScoring ≥ 2.0 SDs below published norms on two or more tests.